Key facts
- It has raised $2.1M; the latest was Later Stage VC ($70K) in Apr 2026.
- Notable investors include GRA Venture Fund, National Cancer Institute, National Institute of General Medical Sciences.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for NovAb
- ·The full record, as it builds
Funding rounds
No funding rounds for NovAb are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NovAb
Developer of monoclonal antibodies (mAbs) designed to utilize variable lymphocyte receptors (VLRs) to develop therapeutic drugs and diagnostic and biomedical research reagents. The company develops leucine-rich repeat motifs that form a rigid binding site structure that is contained within a single polypeptide for immune receptors that are not immunoglobulin (Ig), and a new category of research reagents that recognise glycans, enabling researchers and scientists to enhance biomedical research and therapeutic strategies.
- Sector
- Healthcare
- HQ
- Tucker, GA, United States
- Founded
- 2013
- Employees
- 6
- Website
- novabinc.com/
- Ownership
- Privately Held (backing)
NovAb doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NovAb shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NovAb in its N-PORT filings yet. We sweep new filings monthly.